Thus, LAG-3 blockade may represent a useful strategy to improve the immune response in cancer patients with high LAG-3 expression as it is suggested in a clinical trial in progress (NCT04913922) aiming to study the effect of antibody blockade of LAG-3 and PD-1, in combination with 5-Azacytidine, on survival of patients with relapsed/refractory and elderly AML patients [39]. The gene discussed is PDCD1; the disease is cancer.